Contineum Therapeutics (CTNM) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 0.0% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $329.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | INO |
|---|---|---|
| Share price | $8.68 | $1.76 |
| Market cap | $340.83M | $329.66M |
| 1-day change | -3.98% | +2.92% |
| YTD return | -24.06% | +1.15% |
| 1-year return | -20.69% | 0.00% |
| 5-year return | — | -97.98% |
| EPS (TTM) | $-1.77 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $65.34K |
| Revenue growth (YoY) | — | -69.99% |
| Net income (latest FY) | $-59.98M | $-84.95M |
| Operating margin | — | -132871.32% |
| Net margin | — | -130000.00% |
| 52-week high | $17.79 | $2.72 |
| 52-week low | $6.73 | $0.56 |
| Distance from 52-week high | -51.19% | -35.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.89% | +259.66% |
| Average volume | 776.03K | 11.24M |
| Shares outstanding | 35.35M | 187.31M |
| Employees | 51 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed CTNM by 20.7 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
CTNM vs INO FAQ
Which is bigger, Contineum Therapeutics or Inovio Pharmaceuticals?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $329.66M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, CTNM or INO?
INO returned 0.00% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.